Saibi Shu (赛比舒)赛比舒
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
批准文号:NMPA approval number: 国药准字H19990247
生产企业Manufacturer
- 雅柏药业(中国)有限公司Chinese legal name: 雅柏药业(中国)有限公司
主要成分Active Ingredients
- 沙丁胺醇Shading Anchun
药物知识说明
国药准字H19990247是一种在国家药监局注册认定的药品。该药品含有相关活性成分。
该药品关联的活性成分包括：沙丁胺醇Shading Anchun。这些成分信息来自国家药监局数据库。
您可以探索含有相同成分的其他药品：沙丁胺醇-1477bf65成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 赛比舒) is a medicine registered with the national drug regulatory authority. It contains active ingredient(s) as recorded.
Active ingredients associated with this product: 沙丁胺醇Shading Anchun.
Explore other medicines containing the same ingredient: 沙丁胺醇 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 赛比舒Recorded Chinese name: 赛比舒
- 剂型Dosage form: 胶囊剂Capsules
- 规格Specification: 按C13H21NO3计算 8mgRecorded Chinese composition: 按C13H21NO3计算 8mg
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 雅柏药业(中国)有限公司Chinese legal name: 雅柏药业(中国)有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H19990247
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H19990247
Manufacturer
Chinese legal name: 雅柏药业(中国)有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H19990247
生产企业
雅柏药业(中国)有限公司(国产)
适应症
本品用于治疗支气管哮喘或喘息型支气管炎等伴有支气管痉挛的呼吸道疾病。
用法用量
口服，成人：推荐剂量为一次8mg，一日2次。
不良反应
1.高血压、冠状动脉供血不足、糖尿病、甲状腺机能亢进、心功能不全等患者应慎用。
2.长期使用可形成耐药性，不仅疗效降低，且有加重哮喘的危险。
3.肾上腺素受体兴奋剂敏感者慎用，使用时从小剂量开始。
禁忌
对本品或其他肾上腺素受体激动剂过敏者禁用。
注意事项
1.高血压、冠状动脉供血不足、糖尿病、甲状腺机能亢进、心功能不全等患者应慎用。
2.长期使用可形成耐药性，不仅疗效降低，且有加重哮喘的危险。
3.肾上腺素受体兴奋剂敏感者慎用，使用时从小剂量开始。
贮藏
遮光，密封在干燥处保存。
规格
按C13H21NO3计算 8mg
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.